In this video, Sham Mailankody, MBBS discusses the specific challenges that come with treating relapsed/refractory multiple myeloma.

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT), currently trading at $2.74 and showing significant volatility according to InvestingPro data, in partnership with Bristol Myers Squibb (BMS), ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.